What's $115 Million Between Friends?

What is an option to buy half of Elan (NYSE: ELN  ) and Biogen Idec's (Nasdaq: BIIB  ) multiple sclerosis drug, Tysabri, for an undetermined amount of money worth?

Apparently, $115 million. That's one expensive call option, especially considering that there's a decent chance that it would have never been invoked.

Johnson & Johnson (NYSE: JNJ  ) got the option as part of its deal to buy half of Elan's Alzheimer's drug pipeline. Johnson & Johnson could only have invoked the option if there were a change of ownership at Biogen. In that case, Johnson & Johnson would have had the option to finance Elan's buyout of Biogen's half of their Tysabri partnership, thus making Elan and Johnson & Johnson partners.

No such luck. Biogen cried foul. A court agreed. And Elan had to fix the mess it had gotten itself into.

Johnson & Johnson either thought the option was very valuable, or it figured that Elan was between a rock and a hard place, and decided to squeeze a little more out of the desperate-for-cash biotech. The new terms of the deal remove the Tysabri option, but Johnson & Johnson is only paying $885 million for an 18.4% stake in the company, not the originally agreed-upon $1 billion. That works out to just $8.25 per share -- not much of a premium on yesterday's closing price, considering how much Elan had to give up.

As I wrote when the original deal was announced, the true benefits of this deal for Elan will be determined by the success or failure of its phase 3 Alzheimer's drug, bapineuzumab. Giving up half of its half of the drug -- Wyeth (NYSE: WYE  ) , soon to be Pfizer (NYSE: PFE  ) , owns the other half -- will look like a great move if bapineuzumab fails, and a stupid move if the drug becomes a multibillion-dollar blockbuster. The difference of $115 million won't change that, although it certainly would have been nice to have.

Elan is a Rule Breakers pick. The newsletter is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter and Pfizer is an Inside Value recommendation. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 984906, ~/Articles/ArticleHandler.aspx, 11/27/2014 5:42:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement